Insulin efsitora alfa (LY3209590) is an insulin analog developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found similar to insulin degludec in a phase II trial.
Society and culture
Legal status In June 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Onswik, intended for the treatment of type 2 diabetes. The applicant for this medicinal product is Eli Lilly Nederland B.V.
Names Insulin efsitora alfa is the international nonproprietary name.
Research A systematic review and metanalysis of insulin efsitora alfa, published in 2024, found that it may be useful in the management of type 1 and type 2 diabetes.
References
